Subject	O
disposition	O
.	O

Data	O
from	O
110	O
enrolled	O
subjects	O
were	O
eligible	O
for	O
analysis	O
.	O

The	O
demographics	O
of	O
the	O
study	O
subjects	O
,	O
by	O
site	O
,	O
are	O
recorded	O
in	O
Table	O
1	O
.	O

The	O
population	O
studied	O
was	O
predominantly	O
not	O
HIV	O
infected	O
(	O
92	O
%	O
)	O
,	O
and	O
by	O
the	O
study	O
entry	O
criteria	O
,	O
their	O
probability	O
of	O
infection	O
was	O
considered	O
to	O
be	O
low	O
.	O

The	O
risk	O
categories	O
assigned	O
at	O
the	O
time	O
of	O
study	O
entry	O
were	O
combined	O
into	O
groups	O
for	O
analysis	O
,	O
based	O
on	O
the	O
predisposition	O
for	O
PCP	O
.	O

The	O
analysis	O
groups	O
were	O
as	O
follows	O
:	O
(	O
i	O
)	O
HIV	O
/	O
AIDS	O
,	O
(	O
ii	O
)	O
lung	B-Organ
transplant	O
(	O
one	O
subject	O
with	O
a	O
dual	O
organ	B-Organ
transplant	O
[	O
lung	B-Organ
/	O
kidney	B-Organ
]	O
was	O
included	O
in	O
this	O
category	O
)	O
,	O
(	O
iii	O
)	O
all	O
other	O
organ	B-Organ
transplants	O
and	O
allogeneic	B-Cell
hematopoietic	I-Cell
stem	I-Cell
cell	I-Cell
transplants	O
(	O
HSCT	O
)	O
,	O
(	O
iv	O
)	O
leukemia	B-Cancer
,	O
other	O
hematological	O
disorders	O
,	O
and	O
autologous	O
HSCT	O
,	O
(	O
v	O
)	O
other	O
solid	B-Cancer
tumors	I-Cancer
,	O
and	O
(	O
vi	O
)	O
other	O
nonmalignant	O
conditions	O
.	O

Table	O
1	O
.	O

Subject	O
enrollment	O
,	O
disposition	O
,	O
and	O
demographics	O
by	O
sitea	O

Characteristic	O
Valueb	O

Site	O
1	O
Site	O
2	O
Site	O
3	O
Site	O
4	O

Enrollment	O

Unique	O
subjects	O
18	O
29	O
22	O
62	O

Subjects	O
entering	O
into	O
primary	O
analysisc	O
18	O
22	O
22	O
48	O

Subjects	O
with	O
repeat	O
visits	O
0	O
0	O
0	O
16	O

No	O
.	O
of	O
samples	B-Tissue
assayed	O
18	O
22	O
22	O
70	O

Gender	O

Male	O
7	O
10	O
13	O
29	O

Female	O
11	O
12	O
9	O
19	O

Race	O

Caucasian	O
12	O
4	O
0	O
48	O

Black	O
6	O
13	O
0	O
0	O

Other	O
(	O
nonwhite	O
)	O
0	O
5	O
0	O
0	O

No	O
data	O
0	O
0	O
22	O
0	O

Mean	O
(	O
range	O
)	O
age	O
(	O
yr	O
)	O
57	O
(	O
26	O
-	O
78	O
)	O
54	O
(	O
21	O
-	O
75	O
)	O
52	O
(	O
26	O
-	O
74	O
)	O
56	O
(	O
23	O
-	O
73	O
)	O

Pretest	O
probability	O
of	O
PCP	O

Moderate	O
0	O
3	O
4	O
0	O

Low	O
18	O
19	O
18	O
48	O

Sample	B-Tissue
type	O

BAL	O
18	O
20	O
20	O
43	O

Sputum	B-Organism_substance
0	O
1	O
1	O
0	O

Other	O
LRT	O
0	O
1	O
1	O
5	O

At	O
-	O
risk	O
group	O

HIV	O
/	O
AIDS	O
0	O
3	O
6	O
0	O

Lung	B-Organ
transplant	O
8	O
0	O
1	O
31	O

Other	O
transplants	O
1	O
7	O
3	O
0	O

Leukemia	B-Cancer
1	O
1	O
7	O
0	O

Other	O
solid	B-Cancer
tumors	I-Cancer
2	O
1	O
1	O
7	O

Other	O
nonmalignant	O
conditions	O
6	O
10	O
4	O
10	O

a	O

The	O
testing	O
and	O
enrollment	O
sites	O
for	O
the	O
study	O
were	O
Duke	O
University	O
School	O
of	O
Medicine	O
,	O
Durham	O
,	O
NC	O
;	O
Albert	O
Einstein	O
College	O
of	O
Medicine	O
and	O
Montefiore	O
Medical	O
Center	O
,	O
Bronx	O
,	O
NY	O
;	O
Centre	O
Hospitalier	O
Universitaire	O
Vaudois	O
and	O
University	O
of	O
Lausanne	O
,	O
Lausanne	O
,	O
Switzerland	O
;	O
and	O
Medizinische	O
Universitat	O
and	O
Landeskrankenhaus	O
Natters	O
,	O
Innsbruck	O
,	O
Austria	O
.	O

b	O

Except	O
where	O
otherwise	O
indicated	O
,	O
values	O
are	O
numbers	O
of	O
patients	O
.	O

c	O

Subjects	O
were	O
excluded	O
from	O
analysis	O
if	O
they	O
withdrew	O
consent	O
or	O
if	O
there	O
was	O
inadequate	O
sample	B-Tissue
left	O
for	O
PCR	O
testing	O
.	O

